The drug consists of bupivacaine encapsulated in DepoFoam, the company’s technology that allows the analgesic effects to last longer. The drug is designed to provide 72 hours of post-surgical non-opioid pain relief, according to the website. The FDA expects to complete its review of Exparel by July 2011.
Read the Trading Markets report on Exparel.
Read more on anesthesia:
–Anesthesiologist Tasks Colleagues With Peri-Operative Improvement in 2011
–Blocking Receptor Might Help Control Post-Surgery Pain and Inflammation
–10 Anesthesia Studies Making Recent Headlines
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
